The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Uspenskaia O.V.

Kafedra nervnykh bolezneĭ lechebnogo fakul'teta

Iakhno N.N.

Kafedra nervnykh bolezneĭ i otdel nevrologii i klinicheskoĭ neĭrofiziologii Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Belushkina N.N.

Institut molekuliarnoĭ meditsiny Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Neurochemical markers of neurodegeneration in the early diagnosis of Alzheimer's disease, vascular and mixed dementia

Authors:

Uspenskaia O.V., Iakhno N.N., Belushkina N.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(8): 36‑40

Read: 3443 times

Contact the author
Table of contents

NEUROCHEMICAL MARKERS OF NEURODEGENERATION IN THE EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE, VASCULAR AND MIXED DEMENTIA
NEUROCHEMICAL MARKERS OF NEURODEGENERATION IN THE EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE, VASCULAR AND MIXED DEMENTIA

To cite this article:

Uspenskaia OV, Iakhno NN, Belushkina NN. Neurochemical markers of neurodegeneration in the early diagnosis of Alzheimer's disease, vascular and mixed dementia. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(8):36‑40. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Novel prospects for early diagnosis of cognitive impairment using Eye-tracking technology. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):13-20
Cere­bral microangiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):15-24
Features of facial expressions in patients with cognitive impairment due to Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):104-109
Diagnosis of Alzheimer’s disease using biological markers in corticobasal syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):133-139
Epileptic seizures in patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11):36-43
A new look at blood biomarkers in Alzheimer’s patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):7-13
Neurogenesis in neurodegeneration: multifactorial regu­lation, mechanisms of impairment, and therapeutic stra­tegies. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12):14-21
Pote­ntial and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medi­cine. 2025;(7):94-99
Amyloidogenesis and neurotrophic dysfunction in age-related macu­lar dege­neration in correlation with Alzheimer’s disease. Russian Journal of Archive of Pathology. 2025;(6):61-68
Age-related pathomorphological changes in the brain of non-human primates. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(4-2):143-149
Abstract:

A study of 27 patients with dismnestic variant of moderate cognitive impairment (MCI) and 20 patients with neurodynamic-dysregulatory variant was carried out. The more intensive atrophic process supported by neuroimaging data and changed levels of neurodegeneration biomarkers - phosphorylated tau-protein 181 and beta-amyloid 42 - were found in patients with dismnestic MCI variant. The follow-up study showed that the large number of patients with progressive cognitive disorders associated with conversion to dementia was observed in this group. In conclusion, the determination of the neurochemical markers in the cerebrospinal fluid allows to detect the neurodegenerative process at early stages of the disease and assists in detection of cases with increased risk of Alzheimer's disease.

Keywords:

Alzheimer's disease
vascular dementia
mixed dementia
moderate cognitive impairmеnt
neurodegeneration biomarkers
phosphorylated tau-protein
β-amyloid-42

Authors:

Uspenskaia O.V.

Kafedra nervnykh bolezneĭ lechebnogo fakul'teta

Iakhno N.N.

Kafedra nervnykh bolezneĭ i otdel nevrologii i klinicheskoĭ neĭrofiziologii Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Belushkina N.N.

Institut molekuliarnoĭ meditsiny Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Close metadata

References:

  1. Gavrilova S.I. Bolezn' Al'tsgeimera (dementsiya al'tsgeimerovskogo tipa). V kn.: Neirodegenerativnye bolezni i starenie (Rukovodstvo dlya vrachei). Pod red. I.A. Zavalishina, N.N. Yakhno, S.I. Gavrilovoi. M: 2001; 9-80.
  2. Gavrilova S.I., Zharikov G.A. Lechenie bolezni Al'tsgeimera. Psikhiatriya i psikhofarmakologiya 2001; 3: 2: 21-24.
  3. Damulin I.V. Bolezn' Al'tsgeimera i sosudistaya dementsiya. Pod red. N.N. Yakhno. M: 2002; 86.
  4. Zakharov V.V. Vozrastnye kognitivnye narusheniya. Pod red. N.N. Yakhno. M 2004.
  5. Zakharov V.V., Yakhno N.N. Narusheniya pamyati. M: GeotarMed 2003; 110-111.
  6. MKB-10. Mezhdunarodnaya statisticheskaya klassifikatsiya boleznei i problem, svyazannykh so zdorov'em. Desyatyi peresmotr. Zheneva 1995; 1: 1: 315.
  7. Mkhitaryan E.A., Preobrazhenskaya I.S. Bolezn' Al'tsgeimera i tserebrovaskulyarnye rasstroistva. Nevrol zhurn 2006; 11: Prilozhenie №1: 31-37.
  8. Yakhno N.N. Kognitivnye rasstroistva v nevrologicheskoi klinike. Nevrol zhurn 2006; II: Prilozhenie №1: 4-12.
  9. Yakhno N.N., Zakharov V.V. Legkie kognitivnye narusheniya v pozhilom vozraste. Nevrol zhurn 2004; 1: 4-8.
  10. Yakhno N.N., Lokshina A.B., Zakharov V.V. Legkie i umerennye kognitivnye rasstroistva pri distsirkulyatornoi entsefalopatii. Klinicheskaya gerontologiya 2005; 9: 38-39.
  11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4-th Ed. (DSM-IV). Washington 1994; 143-147.
  12. Blennow K. CSF biomarkers for mild cognitive impairment. J Intern Med 2004; 256: 224-234.
  13. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2: 605-613.
  14. Blennow K., Vanmechelen E., Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 2001; 24: 87-97.
  15. Blennow K., Wallin A., Agren H. et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol-Chem-Neuropathol 1995; 26: 231-245.
  16. Buerger K., Ewers M., Pirttila T. et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006; 129: 3035-3041.
  17. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2003; 2: 15-21.
  18. De Leon M.J., DeSanti S., Zinkowski R. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006; 26: 394-401.
  19. De Leon M.J., Segal S., Tarshish C.Y. et al. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett 2002; 333: 183-186.
  20. Devanand D.P., Liu X., Tabert M.H. et al. Combining Early Markers Strongly Predicts Conversion from Mild Cognitive Impairment to Alzheimer's Disease. Biol Psychiatry 2008; 64: 10: 871-879.
  21. Dubois V., Feldman H.H., Jacova S. et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 8: 734-746.
  22. Dubois B., Picard G., Sarazin M. Early detection of Alzheimer's disease: new diagnostic criteria. Dialogues Clin Neurosci 2009; 11: 2: 135-139.
  23. Dubois V., Slachevsky A., Litvan I., Pillon B. A frontal assessment battery at bedside. Neurology 2000; 55: 1621-1626.
  24. Ferri S.R., Prince M., Brayne C. et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-2117.
  25. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental-state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
  26. Gauthier R.S., Reisberg V., Zaudig M. et al. Mild cognitive impairment. Lancet 2006; 367: 1262-1270.
  27. Grober E., Bushke H., Crystal H. et al. Screening for dementia by memory testing. Neurology 1988; 38: 900-903.
  28. Growdon J.H., Selkoe D.J., Roses A. et al. Consensus report of the Working Group on Biological Markers of Alzheimer's Disease. Ronald and Nancy Reagan Institute of the Alzheimer's Association and National Institute on Aging Working Group on Biological Markers of Alzheimer's Disease. Neurobiol Aging 1998; 19: 109-116.
  29. Hampel H., Goernitz A., Buerger K. Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(l-42) proteins to phosphorylated tau protein. Brain Res Bull 2003; 61: 243-251.
  30. Hughes S.R., Berg L., Danziger W.L. et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566-572.
  31. Kaplan E.F., Goodglass H., Weintraub S. The Boston Naming Test. Boston 1978.
  32. Larrieu S., Letenneur L., Orgogozo J.M. et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002; 59: 1594-1599.
  33. Lezak M.D. Neuropsychology Assessment. New York 1983.
  34. Luis C.A., Loewenstein D.A., Acevedo A. Mild cognitive impairment: directions for future research. Neurology 2003; 61: 438-444.
  35. Matsui T., Nemoto M., Maruyama M. et al. Plasma homocysteine and risk of coexisting silent brain infarction in Alzheimer's disease. Neurodegener Dis 2005; 2: 299-304.
  36. Mufson E.J., Chen E.Y., Cochran E.J. et al. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol 1999; 158: 469-490.
  37. Patterson C., Feightner J.W., Garcia A. et al. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. Cmaj 2008; 178: 548-556.
  38. Petersen R.S., Touchon J. Consensus on mild cognitive impairment. Research and Practice in Alzheimer's Disease 2005; 10: 24-32.
  39. Petersen R.S., Smith G.E., Waring S.C. et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308.
  40. Reitan R.M. Validity of the Trail Making test as an indicator of organic brain damage. Percept Mot Skills 1958; 8: 271-276.
  41. Ritchie K. Mild cognitive impairment: an epidemiological perspective. Dialogues Clin Neurosci 2004; 6: 401-408.
  42. Stroop J.R. Studies of interference in serial verbal reactions. J Experiment Psychology 1935; 18: 643-662.
  43. Vanderstichele K., Van Kerschaver E., Hesse C. et al. Standardization of measurement of beta-amyloid(l-42) in cerebrospinal fluid and plasma. Amyloid 2000; 7: 245-258.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.